Participated · Series B · Jan 2026

Primmune Therapeutics is a clinical-stage therapeutics company focused on designing and developing systemically acting, orally delivered small-molecule toll-like receptor 7 (TLR7) agonists. Its lead candidate, PRTX007, aims to stimulate the innate immune system and is being advanced for cancers and other diseases that respond to immunotherapy. The company plans to launch Study PRTX007-003, a Phase 2 neoadjuvant efficacy trial evaluating PRTX007 in combination with standard-of-care anti-PD-1 therapy for patients with Stage III resectable melanoma. Primmune’s approach could provide a convenient oral alternative to existing injectable immunotherapies. To date, the firm has raised at least $23.3 million in Series B funding, including the latest $8.6 million tranche. These funds will support the upcoming Phase 2 trial and continued development of its TLR7 agonist platform.

Participated · Series A · Jul 2025

Actithera applies medicinal chemistry and radiochemistry to develop next-generation radioligand therapies (RLTs) using a proprietary three-pillar discovery platform. The platform combines rational drug design, first-in-class covalent targeting strategies, and two additional proprietary approaches to optimize tumor residence time while ensuring rapid systemic clearance. Its work on fibroblast activation protein (FAP) produced a FAP-directed RLT development candidate with an optimal pharmacokinetic profile and tumor specificity. The company plans to advance its lead FAP asset into clinical development across multiple indications and to expand its preclinical pipeline. Actithera was founded in 2021 and is headquartered in Oslo, Norway and Cambridge, Massachusetts.

Participated · Seed · Jan 2025

Commit Biologics is developing the Bispecific Complement Engaging (BiCE™) platform, a modular system that uses single‑domain antibodies to engage C1q and direct complement activation against tumor and autoimmune targets. The technology can arm conventional antibodies to enhance complement‑mediated cytotoxicity and modulate innate and adaptive immune responses. Commit spun out of Aarhus University and builds on more than three decades of research. Since emerging from stealth last May, the company has progressed its platform toward drug candidate selection. Proceeds from the recent financing will be used to advance BiCE and work toward drug candidate (DC) selection. The company says the extension of funding extends its cash runway into late 2026. Commit Biologics develops therapies that activate the complement system to kill specific target cells, with applications in cancer and autoimmune disease. Its core product is the Bispecific Complement Engaging (BiCE™) platform, a modular system that can arm antibodies to direct the complement system to selectively kill cancer cells or immune cells that drive autoimmune diseases. The platform is designed to leverage established antibodies, which the company says can cut development times and reduce risk. Commit plans to use the €16M seed financing to accelerate development of the BiCE™ platform. The company was spun out of Aarhus University and builds on more than three decades of research into complement biology. Commit is led by CEO Krishna Polu. Commit Biologics is developing the BiCE technology to fight cancer. The company announced it has received a 5M DKK Innobooster grant from the Innovation Fund Denmark (IFD). The grant is intended to support further development of the BiCE technology. Aarhus University Technology Transfer posted congratulations on LinkedIn about the boost. The funding is presented as an Innobooster grant rather than equity or debt; no additional financial details were disclosed in the article.

Participated · Series B · Oct 2024

SynOx Therapeutics is a late clinical-stage biopharmaceutical company developing emactuzumab, a monoclonal antibody that targets the CSF‑1 receptor to deplete tumor-associated macrophages in Tenosynovial Giant Cell Tumour (TGCT). The company has initiated the TANGENT Phase 3 trial — a global, multi-center, randomized, double-blind, placebo-controlled study planned for about 130 patients — and has dosed its first patients. Early clinical data reported an overall response rate (ORR) of approximately 71%. SynOx is also exploring emactuzumab’s potential in other macrophage-driven disorders, including graft‑versus‑host disease. The recent $92M Series B financing will support the Phase 3 program and further development. SynOx has raised $323.8M to date, was founded in 2020, and operates from Dublin with a presence in Oxford; the company reports 11–50 employees. SynOx Therapeutics is a late-stage clinical biopharmaceutical company developing emactuzumab, a monoclonal antibody that inhibits CSF-1R, for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other CSF-1–related and macrophage-driven diseases. The company is executing TANGENT, a registrational Phase 3 study of emactuzumab. Management, led by CEO Ray Barlow, aims to establish emactuzumab as a best-in-class drug to address unmet medical needs and improve patient quality of life. SynOx is headquartered in Dublin, Ireland and Oxford, UK. Financially, the company recently supplemented its balance sheet with a debt facility after completing a $75M Series B, positioning it to fund ongoing clinical development. The new financing is intended to support completion and advancement of the registrational program. SynOx Therapeutics is a clinical-stage biopharmaceutical spin-out from Celleron Therapeutics focused on developing emactuzumab, a humanized IgG1 CSF‑1R targeted antibody. Emactuzumab is designed to deplete tumour-associated macrophages and has shown a favorable safety profile and encouraging efficacy in diffuse tenosynovial giant cell tumours (TGCT). The company secured exclusive worldwide rights for the clinical development, manufacturing and commercialization of emactuzumab under a license agreement with Roche. SynOx announced a €37M Series A financing to fund continued development in TGCT and other indications. Management says it will focus on generating the data necessary to register the therapy in a time- and cost-efficient way. The team combines biotech and pharma experience and the board includes investor representatives alongside Celleron’s chairman and SynOx’s CEO.

Participated · Series B · Oct 2024

SynOx is a Dublin-based late clinical-stage biopharmaceutical company developing emactuzumab, a CSF-1 receptor (CSF-1R) inhibiting monoclonal antibody for CSF-1 related and macrophage-driven disorders, notably Tenosynovial Giant Cell Tumour (TGCT). Emactuzumab is described in earlier clinical work as a potentially best-in-class therapy with a short treatment cycle, rapid onset of action and long duration of response. Proceeds from the Series B extension are supporting a registrational Phase 3 clinical trial of emactuzumab. SynOx has dosed the first patients in the TANGENT study, a global, multi-centre, randomized, double-blind, placebo-controlled Phase 3 trial. The study’s primary outcome is overall response rate (ORR); secondary outcomes include functional and quality-of-life measures, impact on tumour volume, and duration of response, with approximately 130 patients expected to be enrolled (ClinicalTrials.gov Identifier: NCT05417789). The company raised additional capital in the Series B round to advance emactuzumab toward market for TGCT patients.